Barclays beats profit estimates and ups shareholder payments as equities, investment banking surge

Finance

Barclays and HSBC buildings are seen amid the outbreak of the coronavirus disease (COVID-19), in London, Britain October 20, 2020.
Matthew Childs | Reuters

Barclays beat second-quarter profit expectations on Wednesday and boosted returns to shareholders, with its investment banking and equities businesses posting record incomes.

The British lender posted a quarterly attributable profit of £2.1 billion ($2.9 billion), up from £90 million for the second quarter of 2020. Analysts had expected net reported income of £1.7 billion for the three months until the end of June, according to Refinitiv data.

Equities and investment banking fees were up 38% and 27%, respectively, in the second quarter.

Barclays also announced increased capital distributions to shareholders, with a half-year dividend of 2 pence per share and a further share buyback of up to £500 million.

The bank has also seen a significant reduction in credit loss provisions, as outlined in its first-quarter earnings report.

Barclays shares are up by around 15% year-to-date, but were as much as 31% higher at the end of April.

Other highlights for the quarter:

  • Group revenues hit £5.4 billion, fractionally up from £5.34 billion a year ago.
  • CET 1 ratio, a measure of bank solvency, came in at 15.1%, up from 14.2% a year ago.

Barclays has previously indicated that it expects costs to rise in 2021 compared to the previous year, due to coronavirus-related expenses, a real estate review, further structural cost action and pay increases.

Articles You May Like

The art market is in a correction as big spenders fade
Yields on cash are still ‘well ahead of inflation,’ expert says. Here’s where to put your money now
The Super-Rich Pay Super-Amounts of Taxes, New Treasury Report Finds
Demand for Roth IRA conversions may increase — even without tax hikes from President-elect Donald Trump
Banks are reporting a tenfold surge in digital scams, cybersecurity firm BioCatch says